Literature DB >> 15086460

Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis.

Anja S Mühlfeld1, Stephan Segerer, Kelly Hudkins, Andrew G Farr, Lihua Bao, Damian Kraus, V Michael Holers, Richard J Quigg, Charles E Alpers.   

Abstract

BACKGROUND: Mice overexpressing thymic stromal lymphopoietin (TSLP) develop mixed cryoglobulinemia with renal disease closely resembling human cryoglobulin-associated membranoproliferative glomerulonephritis (MPGN), including glomerular deposits of immunoglobulins and complement. We assessed the effect of complement inhibition through overexpression of Crry (complement receptor-1 related gene/protein Y), which blocks the classic and alternative pathway of complement activation through inhibition of the C3 convertase, in cryoglobulinemia-associated immune complex glomerulonephritis.
METHODS: TSLP transgenic mice were crossbred with animals overexpressing Crry. Mice were sacrificed after 50 days (females) or 120 days (males), and kidneys, blood, and urine were collected from seven mice of each experimental group (wild type, Crry transgenic, TSLP transgenic, and Crry/TSLP doubly transgenic).
RESULTS: TSLP/Crry doubly transgenic animals demonstrated expected serum levels of Crry. Renal involvement, both in TSLP transgenic and TSLP/Crry doubly transgenic animals, was characterized by glomerular matrix expansion, macrophage influx, activation of mesangial cells, and deposition of immunoglobulins and complement. Overexpression of Crry did not result in significant improvement of renal pathology or laboratory findings. Expression of recombinant soluble Crry was confirmed by enzyme-linked immunosorbent assay (ELISA) in Crry transgenic animals. However, formation of the membrane attack complex C5b-9 as a marker of terminal active complement components and represented by glomerular C9 staining could not be inhibited in Crry transgenic TSLP mice.
CONCLUSION: These results indicate that overexpression of Crry was not sufficient to prevent renal injury in TSLP transgenic mice. We suggest that the inhibitory capacity of Crry may be overwhelmed by chronic complement activation. Further studies need to address the role of complement in cryoglobulinemic glomerulonephritis before therapeutic complement inhibition can be attempted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086460     DOI: 10.1111/j.1523-1755.2004.00495.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

1.  Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease.

Authors:  Jolanta Kowalewska; Anja S Mühlfeld; Kelly L Hudkins; Matthew M Yeh; Andrew G Farr; Jeffrey V Ravetch; Charles E Alpers
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

2.  Costimulatory molecule VSIG4 exclusively expressed on macrophages alleviates renal tubulointerstitial injury in VSIG4 KO mice.

Authors:  Yan Li; Yi-Qin Wang; Dai-Hong Wang; Wei-Ping Hou; Ying Zhang; Ming Li; Fu-Rong Li; Jiao Mu; Xiang Du; Fang Pang; Fa-Huan Yuan
Journal:  J Nephrol       Date:  2014-01-15       Impact factor: 3.902

3.  Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis.

Authors:  Masayuki Iyoda; Kelly L Hudkins; Shirly Becker-Herman; Tomasz A Wietecha; Miriam C Banas; Shunhua Guo; Almut Meyer-Bahlburg; Jolanta Kowalewska; Gang Liu; Steven F Ziegler; David J Rawlings; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 10.121

4.  Deletion of activating Fcgamma receptors does not confer protection in murine cryoglobulinemia-associated membranoproliferative glomerulonephritis.

Authors:  Shunhua Guo; Anja S Mühlfeld; Tomasz A Wietecha; Carine J Peutz-Kootstra; Jolanta Kowalewska; Kenneth Yi; Min Spencer; Warangkana Pichaiwong; Falk Nimmerjahn; Kelly L Hudkins; Charles E Alpers
Journal:  Am J Pathol       Date:  2009-06-15       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.